How to appeal a UnitedHealthcare solid-organ transplant denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for solid-organ transplant

Cited policy: OptumRx Belatacept (Nulojix) Prior Authorization for Kidney Transplant Maintenance

Adult (>=18 yr) kidney transplant recipient. EBV-seropositive at time of transplantation (mandatory per FDA label, PTLD risk in EBV-seronegative). Used in combination with basiliximab induction, mycophenolate, and corticosteroids per BENEFIT regimen. Not for liver transplant (FDA boxed warning — increased graft loss + death in liver tx).

How UnitedHealthcare denies solid-organ transplant — and how to counter it

Where UnitedHealthcare pushes back: 1) Step therapy: must fail tacrolimus or cyclosporine first; 2) Off-label given mTOR availability; 3) Cost vs generic CNI.

Counter-arguments that hold up: Belatacept FDA-approved Jun 15, 2011 as ALTERNATIVE to calcineurin inhibitors — label does NOT require prior CNI failure. BENEFIT 7-yr extension (Vincenti NEJM 2016;374:333-343) — 43% reduction in death/graft loss + superior mean eGFR vs cyclosporine. BENEFIT-EXT (Durrbach AJT 2010) — same direction in extended-criteria donors. Belatacept avoids CNI nephrotoxicity, NODAT, neurotoxicity. EBV-seropositive verified — patient meets only label requirement. Cite KDIGO 2009 + AST community-of-practice.

What UnitedHealthcare typically denies for solid-organ transplant

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For solid-organ transplant, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the solid-organ transplant treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Basiliximab (Simulect)
• rATG (Thymoglobulin)
• Alemtuzumab (Campath)
• Tacrolimus IR (Prograf)
• Tacrolimus ER (Astagraf-XL)
• Tacrolimus ER (Envarsus-XR)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.